# Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Study · id `cardio:ct-nct03060980` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03060980](<https://clinicaltrials.gov/study/NCT03060980>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03060980

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 245 participants.

## Technical summary

Registry record NCT03060980. Randomized; no masking; primary purpose treatment. Start 2017-03-03 (actual); primary completion 2018-01-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 245 participants (enrolled count; ClinicalTrials.gov record NCT03060980, source copy `cardio:ctgov-nct03060980-2019-03-07`, retrieved 2026-10-26)
- Started: 2017-03-03 (actual) (ClinicalTrials.gov record NCT03060980, source copy `cardio:ctgov-nct03060980-2019-03-07`, retrieved 2026-10-26)
- Primary completion: 2018-01-26 (actual) (ClinicalTrials.gov record NCT03060980, source copy `cardio:ctgov-nct03060980-2019-03-07`, retrieved 2026-10-26)
- Completion: 2018-01-26 (actual) (ClinicalTrials.gov record NCT03060980, source copy `cardio:ctgov-nct03060980-2019-03-07`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03060980, source copy `cardio:ctgov-nct03060980-2019-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03060980-2019-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): ITCA 650 20/60 mcg/day
- Intervention (Drug): Empagliflozin (oral)
- Intervention (Drug): Glimepiride (oral)
- Lead sponsor: Intarcia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Intarcia Therapeutics (`cardio:org-intarcia-therapeutics`)

## Provenance

Content hash: 495e4212b88adf7d533fb12edac92723e1e3de2520da93c3642be1562eee3e64
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
